Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)–positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.7515 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7515-7515 ◽

Author(s):

D. Kim ◽

J. K. Lee ◽

H. S. Park ◽

K. Kulig ◽

T. M. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Alk Inhibitors ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

Annals of Oncology ◽

10.1016/s0923-7534(20)32041-x ◽

2012 ◽

Vol 23 ◽

pp. xi44

Author(s):

P.-C. Yang ◽

R. Salgia ◽

B. Solomon ◽

A.T. Shaw ◽

D.R. Camidge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Visual Effects ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.09.131 ◽

2019 ◽

Vol 14 (11) ◽

pp. S1171-S1172

Author(s):

T. Leal ◽

H. Wakelee ◽

K.L. Reckamp ◽

A. Chiappori ◽

G.R. Oxnard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

194TiP eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30467-2 ◽

2018 ◽

Vol 13 (4) ◽

pp. S116 ◽

Author(s):

L. Horn ◽

Y-L. Wu ◽

M. Reck ◽

C. Liang ◽

F. Tan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Randomized Study ◽

Small Cell Lung ◽

Phase 3 ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors

Cancer Management and Research ◽

10.2147/cmar.s260274 ◽

2020 ◽

Vol Volume 12 ◽

pp. 6615-6628 ◽

Author(s):

Abhay Singh ◽

Hongbin Chen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Optimal Care ◽

Alk Inhibitors ◽

Anaplastic Lymphoma ◽

Download Full-text

Systematic Literature Review (SLR) Of Sequencing Of Anaplastic Lymphoma Kinase (ALK) Inhibitors In ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Value in Health ◽

10.1016/j.jval.2018.04.291 ◽

2018 ◽

Vol 21 ◽

pp. S49-S50 ◽

Author(s):

SM Barrows ◽

K Wright ◽

C Copley-Merriman ◽

JA Kaye ◽

MD Chioda ◽

...

Keyword(s):

Lung Cancer ◽

Literature Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Alk Inhibitors ◽

Anaplastic Lymphoma ◽

Download Full-text

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps9115 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS9115-TPS9115 ◽

Author(s):

Leora Horn ◽

Yi-Long Wu ◽

Martin Reck ◽

Heather A. Wakelee ◽

Chris Liang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Randomized Study ◽

Small Cell Lung ◽

Phase 3 ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

PD.1.03 Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.07.028 ◽

2018 ◽

Vol 13 (9) ◽

pp. S156

Author(s):

T. Leal ◽

H. Wakelee ◽

K. Reckamp ◽

S. Waqar ◽

S. Patel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Line Treatment ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Regional reporting of the incidence of Anaplastic Lymphoma Kinase (ALK) mutation in 379 non-small-cell lung cancer (NSCLC) patients from Kolkata (Eastern India): Using IHC as the diagnostic modality in a considerable subset

Lung Cancer ◽

10.1016/s0169-5002(18)30033-3 ◽

2018 ◽

Vol 115 ◽

pp. S3

Author(s):

K. Chatterjee ◽

R. Bhowmik ◽

B. Chattopadhyay

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Eastern India ◽

Small Cell Lung ◽

Diagnostic Modality ◽

Anaplastic Lymphoma ◽

Download Full-text

P1.03-010 Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.814 ◽

2017 ◽

Vol 12 (11) ◽

pp. S1954

Author(s):

R. Imase ◽

S. Endo ◽

Y. Sasahara ◽

T. Shinmura ◽

T. Ozawa ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Download Full-text